Hilsenbeck SG - Search Results

1

Preclinical activity of ilmofosine against human tumor colony forming units in vitro.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff DD. Hanauske AR, et al. Among authors: hilsenbeck sg. Anticancer Drugs. 1992 Feb;3(1):43-6. doi: 10.1097/00001813-199202000-00008. Anticancer Drugs. 1992. PMID: 1623215

2

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.

Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Hanauske AR, et al. Among authors: hilsenbeck sg. Anticancer Drugs. 1992 Apr;3(2):121-4. doi: 10.1097/00001813-199204000-00008. Anticancer Drugs. 1992. PMID: 1356030

3

Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Banks P, Stuckey J, Leahy M, Von Hoff DD. Hanauske AR, et al. Among authors: hilsenbeck sg. J Immunother (1991). 1992 Apr;11(3):155-8. doi: 10.1097/00002371-199204000-00001. J Immunother (1991). 1992. PMID: 1515420

4

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD. Hanauske AR, et al. Among authors: hilsenbeck sg. Anticancer Drugs. 1992 Apr;3(2):143-6. doi: 10.1097/00001813-199204000-00012. Anticancer Drugs. 1992. PMID: 1525392

5

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA 3rd, Degen D, Von Hoff DD. Shimada Y, et al. Among authors: hilsenbeck sg. Anticancer Drugs. 1994 Apr;5(2):202-6. doi: 10.1097/00001813-199404000-00011. Anticancer Drugs. 1994. PMID: 8049503

6

In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.

Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD. Hanauske AR, et al. Among authors: hilsenbeck sg. Eur J Cancer. 1993;29A(3):423-5. doi: 10.1016/0959-8049(93)90400-a. Eur J Cancer. 1993. PMID: 8398345

7

Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.

Diab SG, Hilsenbeck SG, Izbicka E, Weitman SD, Von Hoff DD. Diab SG, et al. Among authors: hilsenbeck sg. Anticancer Drugs. 1999 Mar;10(3):303-7. doi: 10.1097/00001813-199903000-00009. Anticancer Drugs. 1999. PMID: 10327037

8

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.

Burris HA 3rd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Burris HA 3rd, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20. doi: 10.1093/jnci/84.23.1816. J Natl Cancer Inst. 1992. PMID: 1331485

9

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD. Britten CD, et al. Cancer Chemother Pharmacol. 1999;44(2):105-10. doi: 10.1007/s002800050953. Cancer Chemother Pharmacol. 1999. PMID: 10412943

10

Investigation of taxol as a potential radiation sensitizer.

Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Choy H, et al. Cancer. 1993 Jun 1;71(11):3774-8. doi: 10.1002/1097-0142(19930601)71:11<3774::aid-cncr2820711147>3.0.co;2-0. Cancer. 1993. PMID: 8098270

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

371 results

Search Page

Filters